Back to top
more

Zymeworks (ZYME)

(Delayed Data from NSDQ)

$26.71 USD

26.71
1,043,167

+0.71 (2.73%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $26.75 +0.04 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (143 out of 243)

Industry: Medical - Biomedical and Genetics

Brokerage Reports

Research for ZYME

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Zymeworks Inc. [ZYME]

Reports for Purchase

Showing records 1 - 20 ( 80 total )

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/12/2026

Company Report

Pages: 4

Option Platform

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/06/2026

Company Report

Pages: 6

Several Incrementally Positive Events; 4Q25 Financials; Raising PT to $46

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

01/12/2026

Company Report

Pages: 5

HERIZON-GEA-01 Primary Analysis Details - Generally Positive With Some Gives and Takes

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

12/18/2025

Daily Note

Pages: 22

2026 TOP IDEAS

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 75.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

11/18/2025

Company Report

Pages: 6

Zanidamatab Scores Another Win, This Time in 1L HER2+ GEA Cancer; Raising PT to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/18/2025

Company Report

Pages: 3

Phase 3 GEA Top Line: Double Stretching to a Triple.

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

10/24/2025

Company Report

Pages: 6

Initial ZW191 Data Presented at Triple Meeting; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/24/2025

Company Report

Pages: 3

Elahert?n. ZW191 Showing Signs of Best-in-Class.

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/14/2025

Company Report

Pages: 4

Revisiting our Estimates; Upgrading to Buy With $26 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/03/2025

Company Report

Pages: 3

ZW171 Terminated. Zanidatamab and Other Early Assets Remain Reasons to BUY.

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

07/03/2025

Company Report

Pages: 5

Zanidatamab Approved in 2L+ BTC in the E.U.; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/02/2025

Company Report

Pages: 4

Zanidatamab Approved in China; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/20/2025

Company Report

Pages: 5

1Q25 Financials Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/10/2025

Company Report

Pages: 4

4Q24 Financials Reported; Adjusting PT to $13; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/22/2024

Company Report

Pages: 4

Zanidatamab Receives FDA Approval in 2L+ BTC; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/21/2024

Company Report

Pages: 3

First Approval for Zanidatamab ( Ziihera ).

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/01/2024

Company Report

Pages: 5

Preclinical Data Presented; 3Q24 Financials Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

10/22/2024

Company Report

Pages: 5

ZW171 Phase 1 Trial Dosing Initiation; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

09/25/2024

Company Report

Pages: 5

Preclinical Data for ZW220 ZW251 Expected at Triple Meeting; Raising PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 10.00

Research Provided by a Third Party

Company: Zymeworks Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/18/2024

Company Report

Pages: 8

Numerous Takeaways from ESMO; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BURNS R

Price: 25.00

Research Provided by a Third Party